IGF1 and Alzheimer disease: Compared to AD mice, AD/PAPP-A KO mice had reduced amyloid plaque number in the cortex and hippocampus, along with reduced plaque size; reduced astrocytosis, indicative of neuroinflammation; reduced IGF-I activity in the brain; and improved cognitive behavior (113).